Clinical effect and safety of artesunate in treatment of advanced retinoblastoma
ZHANG Yuanyuan1, MIAO Lixia2, SUN Yanfeng2, WANG Jun2, LI Yanshan2, LIU Hongyan2, YUAN Hailian2, ZHANG Xianglan2,YANG Xinji3, LIU Qiuling1,2
1. Anhui Medical University, Hefei 230032, China; 2. Department of Pediatrics, 3. Department of Orbital Disease Research Institute, the General Hospital of Chinese People’s Armed Police Forces, Beijing 100039, China
Abstract：Objective To study the clinical effect and safety of artesunate combined with conventional therapeutic schedule for children with advanced retinoblastoma. Methods We summarized clinical data of 11 cases who were treated with artesunate combined with conventional therapeutiy with advanced retinoblastoma as combination group between Octobor 1 2012 to January 31 2014 in the General Hospital of Chinese People’s Armed Police Forces. At the same time, 11 cases of advanced retinoblastoma with single conventional therapeutic schedule were selected as control group. The efficacy and safety were reviewed. Results (1)There were two of four(2/4,50%) cases of successfully reserved eyeball in children with intraocular D-E stage, and two cases in five(2/5,40%) received surgery opportunity with extraocular stage in combination group; two cases(2/7,28.6%) of successful reserved eyeball with intraocular D-E stage in seven patients, and one case(1/3,33.3%) received surgey opportunity with extraocular stage in three children in control group. (2)By the end of February 1,2015, the median progression-free survival and the median overall survival were 18.2 months and 21.8 months respectively in the combination group, which compared with control group(the median progression-free survival was 18.4 months and the median overall survival was 21 months), the difference was not statistically significant. (3)All patients did not show allergic reactions during the artesunate therapy and vital signs were stable. No significant difference was found in toxicity between the the two groups (P>0.05). Cnclusion Preliminary study results show that artesunate used for clinical treatment of advanced RB has certain curative effect without extra side effects.
Linn M A. Intraocular retinoblastoma: the case for a new group classification[J]. Ophthalmol Clin North Am, 2005, 18(1):41-53.
[1]
Dimaras H, Kimani K, Dimba E A, et al. Retinoblastoma[J]. Lancet, 2012, 379(4):1436-1446.
[12]
Gobin Y P, Dunkel I J, Marr B P, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience[J]. Arch Ophthalmol, 2011, 129(6):732-737.
[13]
Qaddoumi I, Bass J K, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma[J]. J Clin Oncol, 2012, 30(10):1034-1041.
[2]
Maccarthy A, Draper G J, Steliarova-Foucher E, et al. Retinoblastoma incidence and Survival in European children (1978-1997)[J]. Eur J Cancer, 2006, 42(13):2029-2102.
Efferth T, Sauerbrey A, Olbrich A, et al. Molecular modes of action of artesunate in tumor cell lines[J]. Mol Pharmacol, 2003, 64(2):382-394.
[14]
Chan H S, DeBoer G, Thiessen J J, et al. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation[J]. Clin Cancer Res, 1996, 2(9):1499-1508.
[6]
Sadava D, Phillips T, Lin C, et al. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells[J]. Cancer Lett, 2002, 179(2):151-156.
[15]
Miller L H, Su X. Artemisinin discovery from the Chinese herbal[J]. Cell, 2011, 146(6):855-858.
[7]
Efferth T, Volm M. Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate[J]. In Vivo, 2005, 19(1):225-232.
[16]
Amin N C, Fabre H, Blanchin M D, et al. Determination of artemether and lumefantrine in anti-malarial fixed-dose combination tablets by microemulsion electrokinetic chromatography with short-end injection procedure[J]. Malar J, 2013, 12: 202.
Gobin Y P, Dunkel I J, Marr B P, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience[J]. Arch Ophthalmol, 2011, 129(6):732-737.
[20]
Zhao F, Dimaras H, Massey C, et al. Pre-encleation chemotherapy for eyes severely affected by retinoblastoma masks risks of tumor extension and increases death from metastasis [J].J Clin Oncol, 2011, 29(7):845-851.
[13]
Qaddoumi I, Bass J K, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma[J]. J Clin Oncol, 2012, 30(10):1034-1041.
[14]
Chan H S, DeBoer G, Thiessen J J, et al. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation[J]. Clin Cancer Res, 1996, 2(9):1499-1508.
Miller L H, Su X. Artemisinin discovery from the Chinese herbal[J]. Cell, 2011, 146(6):855-858.
[16]
Amin N C, Fabre H, Blanchin M D, et al. Determination of artemether and lumefantrine in anti-malarial fixed-dose combination tablets by microemulsion electrokinetic chromatography with short-end injection procedure[J]. Malar J, 2013, 12: 202.
[17]
Efferth T, Dunstan H, Sauerbrey A, et al. Theanti-malarial artesunate is also active against cancer[J]. Int J Oncol, 2001, 18(4):767-773.
Zhao F, Dimaras H, Massey C, et al. Pre-encleation chemotherapy for eyes severely affected by retinoblastoma masks risks of tumor extension and increases death from metastasis [J].J Clin Oncol, 2011, 29(7):845-851.
2015, Vol. 26 
